![]() |
3PO
- 英文名称:3PO
- 品牌:WYTSCI
- 产地:进口
- 型号:1MG
- 货号:WT-AY-B11313
- cas:18550-98-6
- 价格: ¥1/mg
- 发布日期: 2025-04-10
- 更新日期: 2025-05-23
产品详请
产地 | 进口 |
品牌 | WYTSCI |
货号 | WT-AY-B11313 |
用途 | 科研检测 |
英文名称 | 3PO |
包装规格 | 1MG |
CAS编号 | 18550-98-6 |
别名 | 3PO |
纯度 | 98+% |
分子式 | |
是否进口 | 是 |
纯度:99% by HPLC,;NMR (Conforms)
分子式:C13H10N2O
分子量:210.23
溶剂:DMSO (15 mg/ml) Ethanol (5 mg/ml)
性状:Pale yellow solid
存储:-20°C
Activity (short version):6-Phosphofructo-2-kinase (PFKFB3) inhibitor
Function / Pharmacology:3PO is an inhibitor of the metabolic enzyme 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3). PFKFB3 is constitutively expressed by neoplastic cells and is required for the high glycolytic rate (Warburg Effect) of these cells. 3PO inhibits PFKFB3 (IC50 = 1.4 – 24 μM for various cancer cell lines), suppresses glucose uptake, and lowers intracellular concentrations of Fru-2,6-BP, lactate, ATP, NAD+, and NADH.1 Inhibition of cancer cell metabolism via blocking the action of PFKFB3 has been studied in various models.2-4 Inhibition of PFKFB3 has been shown to induce autophagy as a survival mechanism in cancer cells.5 3PO has also been used to reduce pathological angiogenesis.6
分子式:C13H10N2O
分子量:210.23
溶剂:DMSO (15 mg/ml) Ethanol (5 mg/ml)
性状:Pale yellow solid
存储:-20°C
Activity (short version):6-Phosphofructo-2-kinase (PFKFB3) inhibitor
Function / Pharmacology:3PO is an inhibitor of the metabolic enzyme 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3). PFKFB3 is constitutively expressed by neoplastic cells and is required for the high glycolytic rate (Warburg Effect) of these cells. 3PO inhibits PFKFB3 (IC50 = 1.4 – 24 μM for various cancer cell lines), suppresses glucose uptake, and lowers intracellular concentrations of Fru-2,6-BP, lactate, ATP, NAD+, and NADH.1 Inhibition of cancer cell metabolism via blocking the action of PFKFB3 has been studied in various models.2-4 Inhibition of PFKFB3 has been shown to induce autophagy as a survival mechanism in cancer cells.5 3PO has also been used to reduce pathological angiogenesis.6